Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells

[1]  T. Sullivan,et al.  Lack of a role for transforming growth factor-β in cytotoxic T lymphocyte antigen-4-mediated inhibition of T cell activation , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[2]  B. Pasche.  Role of transforming growth factor beta in cancer , 2001, Journal of cellular physiology.

[3]  D. Pardoll,et al.  Cd40-Independent Pathways of T Cell Help for Priming of Cd8+ Cytotoxic T Lymphocytes , 2000, The Journal of experimental medicine.

[4]  R. Flavell,et al.  Abrogation of TGFβ Signaling in T Cells Leads to Spontaneous T Cell Differentiation and Autoimmune Disease , 2000 .

[5]  J. Altman,et al.  Soluble Antigen and CD40 Triggering Are Sufficient to Induce Primary and Memory Cytotoxic T Cells1 , 2000, The Journal of Immunology.

[6]  D. Pardoll,et al.  CD 40-independent Pathways of T Cell Help for Priming of CD 8 1 Cytotoxic T Lymphocytes , 2000 .

[7]  A. Khoruts,et al.  CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism. , 1999, Immunity.

[8]  J. Allison,et al.  In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[9]  J. Allison,et al.  Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation , 1999, The Journal of experimental medicine.

[10]  Y. Tokura,et al.  Depletion of IL-10- and TGF-β-Producing Regulatory γδ T Cells by Administering a Daunomycin-Conjugated Specific Monoclonal Antibody in Early Tumor Lesions Augments the Activity of CTLs and NK Cells , 1999, The Journal of Immunology.

[11]  A. Green,et al.  Expression and secretion of TGF-beta isoforms and expression of TGF-beta-receptors I, II and III in normal and neoplastic human breast. , 1999, International journal of oncology.

[12]  C. Chan,et al.  Pregnancy ameliorates induction and expression of experimental autoimmune uveitis. , 1999, Journal of immunology.

[13]  C. Lowenstein,et al.  The Central Role of CD4+ T Cells in the Antitumor Immune Response , 1998, The Journal of experimental medicine.

[14]  S. Wahl,et al.  Engagement of Cytotoxic T Lymphocyte–associated Antigen 4 (CTLA-4) Induces Transforming Growth Factor β (TGF-β) Production by Murine CD4+ T Cells , 1998, The Journal of experimental medicine.

[15]  Anita B. Roberts,et al.  REGULATION OF IMMUNE RESPONSES BY TGF-β* , 1998 .

[16]  K. Abe,et al.  Immunosuppressive activity of cloned natural killer (NK1.1+) T cells established from murine tumor-infiltrating lymphocytes. , 1997, Journal of immunology.

[17]  L. Gorelik,et al.  Insight into the mechanism(s) through which TNF promotes the generation of T cell-mediated antitumor cytotoxicity by tumor bearer splenic cells. , 1996, Journal of immunology.

[18]  J. Allison,et al.  Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.

[19]  H. Maeda,et al.  TGF-beta contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice. , 1996, Journal of immunology.

[20]  J. Foekens,et al.  Transforming growth factor beta secretion from primary breast cancer fibroblasts , 1995, Molecular and Cellular Endocrinology.

[21]  R. Matusik,et al.  Prostate cancer in a transgenic mouse. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[22]  B. Nelson,et al.  Interleukin‐2 suppresses activated macrophage intracellular killing activity by inducing macrophages to secrete TGF‐β , 1994, Journal of leukocyte biology.

[23]  D. Tuveson,et al.  A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Susumu Tonegawa,et al.  RAG-1-deficient mice have no mature B and T lymphocytes , 1992, Cell.

[25]  M. Awwad,et al.  Immunologically mediated regression of a murine lymphoma after treatment with anti-L3T4 antibody. A consequence of removing L3T4+ suppressor T cells from a host generating predominantly Lyt-2+ T cell- mediated immunity , 1988, The Journal of experimental medicine.

[26]  M. Bevan,et al.  Introduction of soluble protein into the class I pathway of antigen processing and presentation , 1988, Cell.